Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

NCT06797336 is registered in ClinicalTrials.gov with PAQ Therapeutics, Inc. as lead sponsor.

NCT NCT06797336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06797336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Lead sponsor
PAQ Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 19, 2024
Completion date
June 16, 2027
Enrollment
300 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor